Expert-authored slides on selecting among current guideline-recommended initial ART regimens, identifying appropriate switch strategies for patients with virologic suppression on 3-drug ART, including 2-drug oral therapy and long-acting 2-drug injectable therapy options, and new data on effective management of virologic breakthrough with NNRTI-based regimens.
Expert-authored slides reviewing the latest data on investigational antiretroviral agents in later stages of development and on additional investigational approaches to HIV management, including broadly neutralizing antibodies, vaccines, and cure strategies
My take on how 2-drug regimens and investigational agents are expanding our options for successful antiretroviral therapy in treatment-naive patients, virally suppressed patients switching regimens, and potentially to patients experiencing virologic failure.
Thoughts on how investigational, long-acting 2-drug regimens involving drugs with novel mechanisms of action may expand treatment options not only for treatment-experienced patients, but also for ART-naive patients in key populations with specific needs.
In this on-demand webcast of a live roundtable, expert faculty consider the integrated approaches needed to address barriers to ART adherence and to select an effective new regimen for an older man with long-standing HIV infection, several comorbidities, and a complex treatment history with multiclass drug resistance. Then the expert panel discusses the best management strategies for a patient who is gaining excess weight on an INSTI- and TAF-containing first-line regimen.
In this on-demand webcast of a live roundtable, expert faculty consider the latest data on currently available and emerging PrEP options as they discuss how to tailor PrEP strategies for people at high risk for HIV and how advances in PrEP continue to be essential for addressing the unique prevention needs of each person. Then the faculty panel explores the effects of the COVID-19 pandemic on HIV care and how infectious disease healthcare professionals can work toward addressing the complex issues of structural racism in medicine that were underscored by COVID-19.
Read my take on what we have learned about weight gain with initial ART and a key question that remains to be answered.
Here’s my take on important changes in the 2021 EACS ART guidelines update.
Diapositivas de expertos que examinan los avances clínicos más importantes en el manejo del VIH desde el año pasado, incluyendo las opciones en desarrollo para la terapia antirretroviral (TAR) de primera línea y las estrategias de cambio para los pacientes virológicamente suprimidos, los regímenes para pacientes con experiencia de tratamiento extensa, las opciones nuevas y expansibles para la prevención del VIH, la orientación y los datos más recientes sobre el aumento de peso con la TAR, las innovaciones futuras en el manejo del VIH, la mitigación de los efectos de la pandemia por COVID-19 en el cuidado del VIH y cómo abordar las desigualdades raciales en los sistemas de atención sanitaria.